In this study, R/M HNSCC patients without Amp11q13 who received anti-PD-1-based therapy exhibited an ORR of 72.5%, a median PFS of 14.3 months, and an OS of 38.2 months. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.